Current Value
$3.151 Year Return
Current Value
$3.151 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
VIXY | -29.46% | $165.69M | 0.85% |
TAIL | -24.64% | $99.76M | 0.59% |
BTAL | -21.14% | $296.79M | 1.43% |
IVOL | -13.53% | $349.27M | 1.02% |
ULST | -11.88% | $662.59M | 0.2% |
XONE | -9.65% | $585.86M | 0.03% |
SGOV | -8.10% | $49.84B | 0.09% |
FTSD | -7.78% | $231.79M | 0.25% |
SHV | -7.74% | $20.67B | 0.15% |
STOT | -7.29% | $253.88M | 0.45% |
SMMU | -7.15% | $888.13M | 0.35% |
FXY | -6.43% | $815.67M | 0.4% |
USDU | -5.90% | $162.92M | 0.5% |
SPTS | -5.63% | $5.78B | 0.03% |
XHLF | -5.59% | $1.73B | 0.03% |
GBIL | -5.40% | $6.38B | 0.12% |
UTWO | -5.29% | $379.36M | 0.15% |
GSST | -5.24% | $918.38M | 0.16% |
XBIL | -5.22% | $783.57M | 0.15% |
FTSM | -4.84% | $6.40B | 0.45% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
GNOM | 39.81% | $44.43M | 0.5% |
ARKG | 36.96% | $1.05B | 0.75% |
IWC | 35.97% | $824.65M | 0.6% |
QTUM | 35.62% | $1.55B | 0.4% |
XBI | 35.18% | $4.95B | 0.35% |
KJUL | 34.06% | $120.75M | 0.79% |
PTH | 33.84% | $101.07M | 0.6% |
PINK | 33.40% | $133.06M | 0.5% |
IBB | 33.00% | $5.36B | 0.45% |
XHE | 32.09% | $165.61M | 0.35% |
PBE | 32.08% | $223.24M | 0.58% |
IWO | 32.07% | $11.48B | 0.24% |
KJAN | 32.05% | $289.38M | 0.79% |
IWM | 31.86% | $64.00B | 0.19% |
VTWO | 31.80% | $13.29B | 0.07% |
HEAL | 31.60% | $43.06M | 0.5% |
GSSC | 31.10% | $586.95M | 0.2% |
IWMY | 30.86% | $118.33M | 1.02% |
PRNT | 30.70% | $76.61M | 0.66% |
SCHA | 30.43% | $17.26B | 0.04% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
TIPX | 0.05% | $1.67B | 0.15% |
TFLO | -0.06% | $6.83B | 0.15% |
TPMN | 0.10% | $30.81M | 0.65% |
VGIT | -0.14% | $31.83B | 0.04% |
IEI | -0.16% | $15.37B | 0.15% |
VTEB | -0.17% | $37.57B | 0.03% |
HTAB | -0.23% | $411.77M | 0.39% |
IBTL | -0.24% | $380.68M | 0.07% |
BILZ | 0.27% | $827.49M | 0.14% |
SHYM | 0.33% | $350.04M | 0.35% |
LGOV | 0.34% | $708.16M | 0.67% |
SCHR | 0.50% | $11.12B | 0.03% |
PZA | 0.51% | $2.84B | 0.28% |
HYMB | -0.62% | $2.62B | 0.35% |
IBTK | 0.62% | $442.63M | 0.07% |
SPTI | 0.68% | $8.78B | 0.03% |
UGA | 0.68% | $72.51M | 0.97% |
TAXF | 0.70% | $488.44M | 0.29% |
IBMS | -0.75% | $88.22M | 0.18% |
IBTJ | -0.77% | $685.71M | 0.07% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MO | -12.18% | $98.96B | +28.98% | 6.98% |
TEF | -9.02% | $29.29B | +23.28% | 6.30% |
AMT | -8.86% | $101.95B | +12.04% | 3.05% |
COR | -8.83% | $58.03B | +32.90% | 0.72% |
MCK | -8.62% | $90.65B | +24.27% | 0.39% |
NEUE | -8.48% | $61.96M | +27.57% | 0.00% |
ACGL | -7.97% | $33.85B | -5.85% | 0.00% |
CBOE | -7.18% | $23.98B | +34.66% | 1.10% |
MVO | -6.87% | $66.13M | -38.96% | 21.90% |
CME | -6.38% | $99.01B | +39.76% | 3.87% |
HUM | -6.26% | $29.19B | -35.27% | 1.84% |
CI | -6.16% | $87.17B | -1.29% | 1.78% |
NHTC | -5.89% | $49.85M | -39.01% | 18.21% |
NYT | -5.82% | $9.07B | +8.59% | 1.02% |
PRT | -5.60% | $51.58M | +9.00% | 10.33% |
BTCT | -5.27% | $18.98M | +37.85% | 0.00% |
HSY | -5.15% | $33.83B | -9.16% | 3.28% |
SJM | -4.87% | $10.19B | -12.30% | 4.52% |
CYCN | -4.85% | $9.63M | +30.43% | 0.00% |
GO | -4.73% | $1.24B | -42.90% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
INOD | -0.01% | $1.55B | +229.06% | 0.00% |
PM | -0.03% | $281.78B | +78.65% | 3.00% |
DRD | 0.04% | $1.12B | +50.52% | 2.12% |
TU | 0.07% | $24.14B | +4.56% | 7.30% |
XBIO | -0.08% | $5.44M | -13.27% | 0.00% |
SBAC | -0.09% | $24.80B | +17.58% | 1.81% |
MNOV | -0.09% | $65.23M | -7.64% | 0.00% |
BE | -0.12% | $5.15B | +81.21% | 0.00% |
WEC | 0.13% | $32.91B | +31.44% | 3.35% |
AFG | 0.13% | $10.43B | +6.16% | 2.49% |
AMED | -0.14% | $3.21B | +6.67% | 0.00% |
HCI | 0.15% | $1.74B | +63.93% | 1.06% |
NTZ | 0.17% | $40.09M | -25.71% | 0.00% |
PULM | 0.18% | $25.57M | +262.69% | 0.00% |
CB | -0.18% | $114.25B | +11.78% | 1.31% |
FATBB | -0.18% | $45.45M | -14.20% | 11.38% |
KNSL | 0.19% | $11.03B | +22.85% | 0.13% |
AQB | 0.24% | $2.84M | -54.35% | 0.00% |
HIG | -0.28% | $35.42B | +24.01% | 1.63% |
CHD | -0.31% | $23.34B | -8.58% | 1.22% |
SeekingAlpha
Cardiff Oncologyâs trial delay and leadership change stir volatility, but strong data potential and a solid cash runway offer upside. Read why CRDF is a buy.
Yahoo
The company said last night, “In addition to today’s medical leadership transition, we are announcing our plan to share an update of clinical data from the ongoing CRDF-004 trial on July 29, at which point we expect to release a substantive dataset.” The data is from Cardiff ‘s lead program in first-line RAS-mutated metastatic colorectal cancer. Shares of Cardiff Oncology (CRDF) are down 8%, or 30c, to $3.10 in premarket trading. Published first on TheFly – the ultimate source for real-time, mar
Yahoo
H.C. Wainwright says the “market overreaction” in shares of Cardiff Oncology (CRDF) “provides an attractive stock price entry point.” Cardiff announced that it will now share updated clinical data from the CRDF-004 trial on July 29, as opposed to the prior guidance of the first half of 2025, driving an after-hours selloff of 13%, the analyst tells investors in a research note. H.C. Wainwright notes that during its discussion with management yesterday, the company disclosed the rationale for this
Yahoo
– Veteran executive with over 20 years of oncology leadership and clinical experience with proven track record of success in bringing development candidates through late-stage clinical development – – Company will hold a conference call on July 29 at 4:30 p.m. ET/1:30 p.m. PT to share additional clinical data from its randomized Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer (“mCRC”) – SAN DIEGO, June 17,
Finnhub
Cardiff Oncology Inc: * CARDIFF ONCOLOGY APPOINTS DR. ROGER SIDHU AS CHIEF MEDICALOFFICER AND ANNOUNCES TIMING FOR THE NEXT UPDATE FROM THECRDF-004 TRIAL IN FIRST-LINE RAS-MUTATED...
Yahoo
– Results from Phase 1b clinical trial evaluating onvansertib + paclitaxel for metastatic triple negative breast cancer demonstrated 40% objective response rate – – The trial evaluated three doses of onvansertib in combination with paclitaxel, and objective responses were observed only at the highest dose of onvansertib – – The combination was well-tolerated and demonstrated a safe and manageable toxicity profile – SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
QURE | 41.51% | $758.81M | +209.38% | 0.00% |
NRIX | 39.08% | $887.38M | -44.23% | 0.00% |
BEAM | 38.38% | $1.69B | -28.30% | 0.00% |
AUPH | 37.54% | $1.17B | +51.31% | 0.00% |
TSE | 36.46% | $122.64M | +48.92% | 1.14% |
RICK | 34.68% | $342.08M | -10.74% | 0.72% |
PUMP | 34.18% | $620.34M | -31.14% | 0.00% |
DMRC | 33.58% | $284.27M | -57.47% | 0.00% |
SYRE | 33.50% | $918.58M | -35.26% | 0.00% |
PHR | 33.47% | $1.70B | +34.39% | 0.00% |
EHTH | 33.25% | $126.77M | -7.73% | 0.00% |
SBGI | 32.32% | $938.52M | +1.20% | 7.39% |
ZYME | 32.26% | $876.06M | +46.53% | 0.00% |
ONEW | 32.22% | $224.14M | -50.16% | 0.00% |
ALK | 31.98% | $5.99B | +22.20% | 0.00% |
IMNM | 31.96% | $763.10M | -27.52% | 0.00% |
ACLX | 31.52% | $3.60B | +18.41% | 0.00% |
ADEA | 31.37% | $1.54B | +26.69% | 1.40% |
ESRT | 30.96% | $1.36B | -13.75% | 1.73% |
ARQT | 30.91% | $1.64B | +47.74% | 0.00% |